ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,127.79
      1.26%
      US Tech 100
      17,446.00
      2.17%
      Dow Jones
      38,675.68
      1.18%
      Brent Oil
      82.765
      0.00%
      Bitcoin
      63,355.56
      -0.84%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Aeglea BioTherapeutics Inc (AGLE)

      7. Aeglea BioTherapeutics Inc (AGLE) News

      AGLE

      Aeglea BioTherapeutics (AGLE)

      Aeglea BioTherapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:AGLE
      DateTimeSourceHeadlineSymbolCompany
      04/30/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:AGLEAeglea BioTherapeutics Inc
      04/25/20244:55PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGLEAeglea BioTherapeutics Inc
      04/25/20244:40PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:AGLEAeglea BioTherapeutics Inc
      04/25/20244:21PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGLEAeglea BioTherapeutics Inc
      04/02/20244:36PMEdgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:AGLEAeglea BioTherapeutics Inc
      04/02/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:AGLEAeglea BioTherapeutics Inc
      04/02/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:AGLEAeglea BioTherapeutics Inc
      04/01/20244:06PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:AGLEAeglea BioTherapeutics Inc
      03/20/20247:14AMEdgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:AGLEAeglea BioTherapeutics Inc
      03/18/20244:06PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:AGLEAeglea BioTherapeutics Inc
      03/18/20248:31AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGLEAeglea BioTherapeutics Inc
      03/14/20244:12PMEdgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:AGLEAeglea BioTherapeutics Inc
      11/28/20234:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGLEAeglea BioTherapeutics Inc
      11/28/20237:33AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGLEAeglea BioTherapeutics Inc
      11/27/20234:36PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGLEAeglea BioTherapeutics Inc
      11/27/20234:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGLEAeglea BioTherapeutics Inc
      11/27/20234:32PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AGLEAeglea BioTherapeutics Inc
      11/27/20234:27PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AGLEAeglea BioTherapeutics Inc
      11/27/20234:25PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGLEAeglea BioTherapeutics Inc
      11/27/20238:30AMPR Newswire (US)Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBDNASDAQ:AGLEAeglea BioTherapeutics Inc
      11/22/20238:45PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGLEAeglea BioTherapeutics Inc
      11/22/20235:00PMPR Newswire (US)Aeglea BioTherapeutics Announces Grants of Inducement AwardsNASDAQ:AGLEAeglea BioTherapeutics Inc
      11/21/202312:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:AGLEAeglea BioTherapeutics Inc
      11/15/20235:18PMEdgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:AGLEAeglea BioTherapeutics Inc
      11/15/20235:14PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGLEAeglea BioTherapeutics Inc
      11/14/20233:13PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:AGLEAeglea BioTherapeutics Inc
      11/09/20234:10PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AGLEAeglea BioTherapeutics Inc
      11/09/20234:06PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGLEAeglea BioTherapeutics Inc
      11/09/20234:05PMPR Newswire (US)Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:AGLEAeglea BioTherapeutics Inc
      11/03/20235:00PMPR Newswire (US)Aeglea BioTherapeutics Announces Grants of Inducement AwardsNASDAQ:AGLEAeglea BioTherapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:AGLE